BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 25573201)

  • 21. Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry.
    Huang TC; Huang SY; Yao M; Lin CY; Hwang WL; Gau JP; Tan TD; Wang PN; Liu YC; Lin SC; Kao RH; Pei SN; Yu MS; Lin HY; Su YC; Chen CC; Li SS; Wu YY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):471-480. PubMed ID: 30119948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
    Merz M; Neben K; Raab MS; Sauer S; Egerer G; Hundemer M; Hose D; Kunz C; Heiß C; Ho AD; Goldschmidt H; Hillengass J
    Ann Oncol; 2014 Jan; 25(1):189-95. PubMed ID: 24356629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
    Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
    Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels.
    Eicher F; Mansouri Taleghani B; Schild C; Bacher U; Pabst T
    Hematol Oncol; 2020 Oct; 38(4):523-530. PubMed ID: 32594534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Franke N; Winter A; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2014 Oct; 55(10):2284-9. PubMed ID: 24354684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
    Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma.
    Holtan SG; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Litzow MR; Gastineau DA; Markovic SN
    Br J Haematol; 2006 Jun; 133(6):628-33. PubMed ID: 16704437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
    Porrata LF; Gertz MA; Litzow MR; Lacy MQ; Dispenzieri A; Inwards DJ; Ansell SM; Micallef IN; Gastineau DA; Elliott M; Hogan WJ; Hayman SR; Tefferi A; Markovic SN
    Clin Cancer Res; 2005 Feb; 11(3):1210-8. PubMed ID: 15709191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Bone Marrow Transplant; 2018 Feb; 53(2):155-161. PubMed ID: 29131152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete response after autologous stem cell transplant in multiple myeloma.
    Kumar L; Iqbal N; Mookerjee A; Verma RK; Sharma OD; Batra A; Pramanik R; Gupta R
    Cancer Med; 2014 Aug; 3(4):939-46. PubMed ID: 24777883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes.
    Kumar L; Gundu N; Kancharia H; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma O; Biswas A; Kumar R; Thulkar S; Mallick S;
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):80-90.e5. PubMed ID: 33129746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.
    Samaras P; Blickenstorfer M; Haile SR; Siciliano RD; Petrausch U; Mischo A; Zweifel M; Honegger H; Schanz U; Stussi G; Taverna C; Bauer S; Knuth A; Stenner-Liewen F; Renner C
    Swiss Med Wkly; 2011; 141():w13203. PubMed ID: 21630163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
    Kim C; Lee HS; Min CK; Lee JJ; Kim K; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC
    Korean J Intern Med; 2015 Sep; 30(5):675-83. PubMed ID: 26354062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
    Goldschmidt H; Baertsch MA; Schlenzka J; Becker N; Habermehl C; Hielscher T; Raab MS; Hillengass J; Sauer S; Müller-Tidow C; Luntz S; Jauch A; Hose D; Seckinger A; Brossart P; Goerner M; Klein S; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Haenel M; Martin H; Lindemann HW; Scheid C; Nogai A; Salwender H; Noppeney R; Besemer B; Weisel K;
    Leukemia; 2021 Apr; 35(4):1134-1144. PubMed ID: 32694619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
    Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.